James A. Schoeneck Sells 7,100 Shares of FibroGen, Inc. (NASDAQ:FGEN) Stock

Posted by on Jun 11th, 2023

FibroGen, Inc. (NASDAQ:FGEN – Get Rating) Director James A. Schoeneck sold 7,100 shares of FibroGen stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $18.03, for a total transaction of $128,013.00. Following the transaction, the director now directly owns 73,722 shares in the company, valued at $1,329,207.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

FibroGen Trading Down 4.5 %

NASDAQ FGEN opened at $16.98 on Friday. FibroGen, Inc. has a 12 month low of $8.67 and a 12 month high of $25.69. The company’s fifty day moving average price is $17.95 and its two-hundred day moving average price is $18.82.

FibroGen (NASDAQ:FGEN – Get Rating) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). The business had revenue of $36.16 million for the quarter, compared to analyst estimates of $31.52 million. FibroGen had a negative return on equity of 879.75% and a negative net margin of 264.63%. The firm’s revenue for the quarter was down 40.6% on a year-over-year basis. During the same period last year, the company posted ($0.68) earnings per share. Analysts predict that FibroGen, Inc. will post -2.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on FGEN. Stifel Nicolaus raised shares of FibroGen from a “hold” rating to a “buy” rating and lifted their price target for the company from $23.00 to $32.00 in a research report on Thursday, June 1st. StockNews.com initiated coverage on shares of FibroGen in a research note on Thursday, May 18th. They issued a “hold” rating for the company. Cowen upped their target price on shares of FibroGen from $15.00 to $25.00 and gave the company a “market perform” rating in a research note on Tuesday, February 28th. Finally, The Goldman Sachs Group upped their target price on shares of FibroGen from $9.00 to $16.00 and gave the company a “sell” rating in a research note on Tuesday, February 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $24.83.

Institutional Trading of FibroGen

Institutional investors and hedge funds have recently modified their holdings of the business. Altshuler Shaham Ltd acquired a new stake in shares of FibroGen during the fourth quarter worth $28,000. Royal Bank of Canada raised its holdings in shares of FibroGen by 45.3% during the third quarter. Royal Bank of Canada now owns 2,314 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 721 shares during the period. Dark Forest Capital Management LP acquired a new stake in shares of FibroGen during the first quarter worth $47,000. Tower Research Capital LLC TRC raised its holdings in shares of FibroGen by 231.2% during the first quarter. Tower Research Capital LLC TRC now owns 3,385 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 2,363 shares during the period. Finally, U.S. Capital Wealth Advisors LLC acquired a new stake in shares of FibroGen during the fourth quarter worth $54,000. 76.89% of the stock is owned by institutional investors and hedge funds.

About FibroGen

(Get Rating)

FibroGen, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer.

Featured Articles

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.